|
市場調査レポート
商品コード
1494288
北米の感染症分子診断市場予測（～2030年）：地域別分析 - タイプ別、エンドユーザー別、用途別、疾患タイプ別、感染タイプ別North America Molecular Diagnostics for Infectious Disease Market Forecast to 2030 - Regional Analysis - by Type (Point-of-Care Testing and Laboratory Testing), End User, Application, Disease Type, Infection Type |
||||||
|
|
|||||||
|
|||||||
| 北米の感染症分子診断市場予測（～2030年）：地域別分析 - タイプ別、エンドユーザー別、用途別、疾患タイプ別、感染タイプ別 |
|
出版日: 2024年03月14日
発行: The Insight Partners
ページ情報: 英文 108 Pages
納期: 即納可能
 |
- 全表示
- 概要
- 図表
- 目次
北米の感染症分子診断の市場規模は、2022年に33億4,515万米ドルに達し、2022年～2030年にCAGR12.2%で成長し、2030年には84億1,970万米ドルに達すると予測されています。
個別化医療における感染症分子診断が北米の感染症分子診断市場を促進
ゲノム研究は、ハイスループット技術の進歩により、より便利で費用対効果の高いものとなっています。分子診断学は、実験室条件下で微生物を培養する従来の検査とは対照的に、迅速な検出結果を提供するため、臨床検査室ではますます不可欠なものとなっています。治療や介入は、患者固有の遺伝的体質や生活習慣、環境などに基づいて、精密医療を用いて患者一人ひとりに合わせて行われます。分子診断学はこのアプローチにおいて重要な役割を果たしています。特定のバイオマーカー、遺伝子変異、遺伝子発現パターンの同定を可能にし、患者の治療に関する意思決定に影響を与えるからです。医薬品開発はますます分子診断学に依存するようになってきています。様々な分子イメージング技術が、進行計画を立て、分子特性を調べ、患者の転帰をモニターするために、スクリーニング、検出、診断、治療、異質性の評価に用いられています。個別化医療は一般に患者のゲノム情報を調べることを目的としており、例えば薬物代謝多型は薬剤の選択と投与量の指針になります。感染症においては、個別化医療の概念を用いて、疾患の原因となる微生物を迅速に同定し、その抗菌薬耐性プロファイルを決定し、その結果に基づいて患者を適切に管理するための適切な抗菌薬治療を確認することができます。感染症のPOC検査は、多くの患者が救命と時間節約の恩恵を受けられるように、医療当局の受け入れ、新しい技術とコミュニケーション基盤の開発、償還政策が必要です。このような技術を臨床に導入することで、各患者の分子標的を特定することが可能になり、疾患の分子的進行の追跡も容易になります。
このように、進化し続ける技術により、感染症分子診断市場は明るい未来を持っていると思われます。
北米の感染症分子診断市場概要
メキシコにおける結核の有病率の増加と結核の診断・治療に対する意識の高まりが、感染症分子診断市場の成長に拍車をかけています。StopTB Partnership Organizationによると、結核に苦しむ人の数は2019年の3万人から2020年には3万1,000人に増加しました。疾病管理予防センター（CDC）の重点の高まりにより、メキシコではいくつかの国際的な検査室プロジェクトが設立されました。これらのプロジェクトには、メキシコのソノラ州とバハ・カリフォルニア州における薬剤感受性および薬剤耐性の結核症例検出のための2つのプロジェクトが含まれます。これら2つのプロジェクトに共通する目標は、州および国の疾病管理プログラムが、リスクのある集団を特定し、その集団に対して迅速な結核検査を実施する能力を構築することです。このような大衆の結核スクリーニングの取り組みは、メキシコ国民の意識を高めています。加えて、医薬品産業の成長、ヘルスケアインフラの新興、診断検査製品に対する需要の高まりが、メキシコの感染症分子診断市場の成長を後押ししています。2021年2月、世界保健機関（WHO）は、小児、青年、成人の結核と薬剤耐性の診断における大幅な進歩を発表しました。結核を検査するために発表された新しい技術クラスは以下の3つです：
- 結核の診断およびリファンピシンとイソニアジドに対する耐性変異の検出のための中複雑度自動核酸増幅検査（NAATs）
- イソニアジドおよび第二選択抗結核薬耐性検出のための低複雑度自動化NAAT
- ピラジナミド耐性検出のためのハイブリダイゼーションベースの高複雑度NAAT
北米の感染症分子診断市場の収益と2030年までの予測（金額）
北米の感染症分子診断市場セグメンテーション
北米の感染症分子診断市場は、タイプ、エンドユーザー、用途、疾患タイプ、感染タイプ、国によって区分されます。
タイプ別では、北米の感染症分子診断市場はポイントオブケア検査と臨床検査に二分されます。2022年の北米の感染症分子診断市場シェアは臨床検査セグメントが大きくなりました。
北米の感染症分子診断市場は、エンドユーザー別にポイントオブケア検査と臨床検査に二分されます。ポイントオブケア検査はさらにヒト検査と獣医検査に二分されます。同様に、臨床検査もヒト検査と獣医検査にさらに二分されます。2022年の北米の感染症分子診断市場シェアは、ポイントオブケア検査によるヒト検査分野が大きくなりました。さらに、臨床検査によるヒト検査セグメントは、2022年の北米の感染症分子診断市場シェアでより大きな割合を占めました。
北米の感染症分子診断市場は、用途別にポイントオブケア検査と臨床検査に二分されます。ポイントオブケア検査はさらに、単一病原体の検出、2種類以上の病原体の検出、新興の新規感染症の評価、生物脅威因子や疾患関連バイオマーカーのサーベイランスと早期検出、抗菌薬耐性プロファイリングに区分されます。同様に、臨床検査はさらに、患者層別化、薬剤レジメン選択、毒性回避、治療モニタリング、疾患素因の検出に分類されます。2022年の北米の感染症分子診断市場シェアは、ポイントオブケア検査による単一病原体の検出分野が最大でした。また、検査室検査による薬剤レジメン選択セグメントは、2022年に北米の感染症分子診断市場で最大のシェアを占めました。
北米の感染症分子診断市場は、疾患タイプ別に、ポイントオブケア検査と臨床検査に二分されます。ポイントオブケア検査はさらに、敗血症（泌尿生殖器／肺／創傷など）、人工関節感染症、心内膜炎、性病、単核球症、A群連鎖球菌、その他に区分されます。同様に、臨床検査はさらに敗血症、人工関節感染症、心内膜炎、STDs、クラミジア、胃腸感染症、結核、H1N1ウイルス、その他に分類されます。2022年の北米の感染症分子診断市場シェアは、ポイントオブケア検査によるSTDs分野が最大でした。また、臨床検査によるSTDs分野は、2022年に北米の感染症分子診断市場で最大のシェアを占めました。
感染症タイプ別では、北米の感染症分子診断市場はポイントオブケア検査と臨床検査に二分されます。ポイントオブケア検査はさらに細菌、ウイルス、真菌、その他に区分されます。同様に、臨床検査はさらに細菌、ウイルス、真菌、その他に分類されます。2022年の北米の感染症分子診断市場シェアは、ポイントオブケア検査による細菌セグメントが最大でした。また、臨床検査による細菌セグメントは、2022年に北米の感染症分子診断市場シェアで最大を占めました。
国別では、北米の感染症分子診断市場は米国、カナダ、メキシコに分類されます。2022年の北米の感染症分子診断市場は米国が支配的でした。
Abbott Laboratories、bioMerieux SA、Bruker Corp、Danaher Corp、DiaSorin SpA、F. Hoffmann-La Roche Ltd、Hologic Inc、Siemens Healthineers AG、Thermo Fisher Scientific Incは北米の感染症分子診断市場に参入している主要企業です。
目次
第1章 イントロダクション
第2章 エグゼクティブサマリー
- 主要洞察
- 北米の感染症分子診断市場：国別、市場の魅力
第3章 調査手法
- 調査範囲
- 2次調査
- 1次調査
第4章 北米の感染症分子診断市場：主要産業力学
- 市場促進要因
- 世界の感染症の急増
- 獣医感染症における分子診断の用途拡大
- 市場抑制要因
- 分子検査に伴う限界
- 市場機会
- 分子診断技術の進歩
- 今後の動向
- 個別化医療における感染症分子診断法
- 影響分析
第5章 感染症分子診断市場-北米市場分析
- 北米の感染症分子診断市場売上高（2022年～2030年）
第6章 北米の感染症分子診断市場の2030年までの収益と予測：タイプ別
- 北米の感染症分子診断市場の収益シェア（2022年・2030年）：タイプ別
- ポイントオブケア検査
- 臨床検査
第7章 北米の感染症分子診断市場の2030年までの収益と予測：エンドユーザー別
- 北米の感染症分子診断市場の収益シェア（2022年・2030年）：エンドユーザー別
- ポイントオブケア検査
- 臨床検査
第8章 北米の感染症分子診断市場の2030年までの収益と予測：用途別
- 北米の感染症分子診断市場の収益シェア（2022年・2030年）：用途別
- ポイントオブケア検査
- 臨床検査
第9章 北米の感染症分子診断市場の2030年までの収益と予測：疾患タイプ別
- 北米の感染症分子診断市場の収益シェア（2022年・2030年）：疾患タイプ別
- ポイントオブケア検査
- 臨床検査
第10章 北米の感染症分子診断市場の2030年までの収益と予測：感染症タイプ別
- 北米の感染症分子診断市場の収益シェア（2022年・2030年）：感染症タイプ別
- ポイントオブケア検査
- 臨床検査
第11章 北米の感染症分子診断市場：国別分析
- 米国
- カナダ
- メキシコ
第12章 業界情勢
- 市場における各社の成長戦略（%）
- 有機的展開
- 無機的展開
第13章 企業プロファイル
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Thermo Fisher Scientific Inc
- bioMerieux SA
- Danaher Corp
- Hologic Inc
- Siemens Healthineers AG
- Bruker Corp
- DiaSorin SpA
第14章 付録
List Of Tables
- Table 1. North America Molecular Diagnostic for Infectious Diseases Market Segmentation
- Table 2. North America Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
- Table 3. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
- Table 4. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
- Table 5. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
- Table 6. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
- Table 7. North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
- Table 8. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
- Table 9. North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
- Table 10. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
- Table 11. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
- Table 12. US Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
- Table 13. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
- Table 14. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
- Table 15. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
- Table 16. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
- Table 17. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
- Table 18. US Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
- Table 19. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
- Table 20. US Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
- Table 21. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
- Table 22. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
- Table 23. Canada Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
- Table 24. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
- Table 25. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
- Table 26. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
- Table 27. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
- Table 28. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
- Table 29. Canada Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
- Table 30. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
- Table 31. Canada Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
- Table 32. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
- Table 33. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
- Table 34. Mexico Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
- Table 35. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
- Table 36. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
- Table 37. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
- Table 38. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
- Table 39. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
- Table 40. Mexico Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
- Table 41. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
- Table 42. Mexico Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
- Table 43. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
- Table 44. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
- Table 45. Organic Developments Done By Companies
- Table 46. Inorganic Developments Done By Companies
- Table 47. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market
List Of Figures
- Figure 1. North America Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
- Figure 2. North America Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics
- Figure 3. Impact Analysis of Drivers and Restraints
- Figure 4. North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030
- Figure 5. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
- Figure 6. Point-of-Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
- Figure 7. Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
- Figure 8. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
- Figure 9. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
- Figure 10. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
- Figure 11. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
- Figure 12. North America: Molecular Diagnostic for Infectious Diseases Market, by Key Country - Revenue (2022) (US$ Million)
- Figure 13. North America Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
- Figure 14. US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
- Figure 15. Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
- Figure 16. Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
- Figure 17. Growth Strategies Done by the Companies in the Market, (%)
The North America molecular diagnostics for infectious disease market was valued at US$ 3,345.15 million in 2022 and is expected to reach US$ 8,419.70 million by 2030; it is estimated to grow at a CAGR of 12.2% from 2022 to 2030.
Molecular Diagnostics for Infectious Diseases in Personalized Medicine Fuels the North America Molecular Diagnostics for Infectious Disease Market
Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.
Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.
North America Molecular Diagnostics for Infectious Disease Market Overview
The increasing prevalence of tuberculosis (TB) and rise in awareness of diagnosis and treatment for TB in Mexico is fueling the growth of the molecular diagnosis for infectious diseases market. According to StopTB Partnership Organization, the number of people suffering from TB rose from 30,000 in 2019 to 31,000 in 2020. The growing focus of Centers for Disease Control and Prevention (CDC) has established several international laboratory projects in Mexico. These projects include two projects for the detection of drug-sensitive and drug-resistant TB cases in Sonora and Baja California, Mexico. The common goal of these two projects is to build capacity for state and national disease control program to identify the group at risk and conduct rapid TB tests on that group. These initiatives for screening the masses for TB are creating awareness in the Mexican population. In addition, the extensively growing pharmaceuticals industry, developing healthcare infrastructure, and elevating demand for diagnostic testing products bolster the molecular diagnostics for infectious diseases market growth in Mexico. In February 2021, the World Health Organization (WHO) announced significant advancements in the diagnosis of TB and drug resistance in children, adolescents, and adults. The three new classes of technologies announced for testing TB were as follows:
- Moderate-complexity automated Nucleic Acid Amplification Tests (NAATs) for the diagnosis of TB and detection of variants resistant to rifampicin and isoniazid
- Low-complexity automated NAATs for detection of resistance to isoniazid and second-line anti-TB agents
- High-complexity hybridization-based NAATs for the detection of resistance to pyrazinamide.
North America Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)
North America Molecular Diagnostics for Infectious Disease Market Segmentation
The North America molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.
Based on type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger North America molecular diagnostics market for infectious disease market share in 2022.
The North America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022.
Based on application, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.
Based on disease type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.
Based on infection type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.
Based on country, the North America molecular diagnostics for infectious disease market is categorized into the US, Canada, and Mexico. The US dominated the North America molecular diagnostics for infectious disease market in 2022.
Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America molecular diagnostics for infectious disease market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
- 2.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. North America Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics
- 4.1 Market Drivers:
- 4.1.1 Surging Prevalence of Infectious Disease Globally
- 4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
- 4.2 Market Restraints
- 4.2.1 Limitations Associated with Molecular Testing
- 4.3 Market Opportunities
- 4.3.1 Advancements in Molecular Diagnostics Technologies
- 4.4 Future Trends
- 4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
- 4.5 Impact Analysis:
5. Molecular Diagnostic for Infectious Diseases Market - North America Market Analysis
- 5.1 North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030
6. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Type
- 6.1 Overview
- 6.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
- 6.3 Point-of-Care Testing
- 6.3.1 Overview
- 6.3.2 Point-of-Care Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4 Laboratory Testing
- 6.4.1 Overview
- 6.4.2 Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by End User
- 7.1 Overview
- 7.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
- 7.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
- 7.2.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
8. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Application
- 8.1 Overview
- 8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
- 8.3 Point-of-Care Testing
- 8.3.1 Overview
- 8.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
- 8.4 Laboratory Testing
- 8.4.1 Overview
- 8.4.2 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
9. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Disease Type
- 9.1 Overview
- 9.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
- 9.3 Point-of-Care Testing
- 9.3.1 Overview
- 9.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
- 9.3.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
- 9.4 Laboratory Testing
- 9.4.1 Overview
- 9.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
- 9.4.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
10. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Infection Type
- 10.1 Overview
- 10.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
- 10.3 Point-of-Care Testing
- 10.3.1 Overview
- 10.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
- 10.4 Laboratory Testing
- 10.4.1 Overview
- 10.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11. North America Molecular Diagnostic for Infectious Diseases Market - Country Analysis
- 11.1 North America Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast To 2030
- 11.1.1 Overview
- 11.1.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country
- 11.1.2.1 US
- 11.1.2.1.1 US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.1.2 US: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
- 11.1.2.1.3 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
- 11.1.2.1.4 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
- 11.1.2.1.5 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
- 11.1.2.1.6 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
- 11.1.2.1.7 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
- 11.1.2.1.7.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
- 11.1.2.1.8 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
- 11.1.2.1.8.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
- 11.1.2.1.9 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
- 11.1.2.1.10 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
- 11.1.2.2 Canada
- 11.1.2.2.1 Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.2.2 Canada: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
- 11.1.2.2.3 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
- 11.1.2.2.4 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
- 11.1.2.2.5 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
- 11.1.2.2.6 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
- 11.1.2.2.7 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
- 11.1.2.2.7.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
- 11.1.2.2.8 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
- 11.1.2.2.8.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
- 11.1.2.2.9 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
- 11.1.2.2.10 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
- 11.1.2.3 Mexico
- 11.1.2.3.1 Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.3.2 Mexico: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
- 11.1.2.3.3 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
- 11.1.2.3.4 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
- 11.1.2.3.5 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
- 11.1.2.3.6 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
- 11.1.2.3.7 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
- 11.1.2.3.7.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
- 11.1.2.3.8 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
- 11.1.2.3.8.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
- 11.1.2.3.9 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
- 11.1.2.3.10 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
- 11.1.2.1 US
12. Industry Landscape
- 12.1 Overview
- 12.2 Growth Strategies Done by the Companies in the Market, (%)
- 12.3 Organic Developments
- 12.3.1 Overview
- 12.4 Inorganic Developments
- 12.4.1 Overview
13. Company Profiles
- 13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Abbott Laboratories
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Thermo Fisher Scientific Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 bioMerieux SA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Danaher Corp
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Hologic Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Siemens Healthineers AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Bruker Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 DiaSorin SpA
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
14. Appendix
- 14.1 About Us
- 14.2 Glossary of Terms
